Dr Reddy's Laboratories Ltd

NYSE:RDYUnited States

May 21, 2024

Show headlines and story abstract

• Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading, from 10:40AM ET on Tuesday May 21, 2024 by MT Newswires

  10:40AM ET on Tuesday May 21, 2024 by MT Newswires
  Companies Mentioned: IBN, INFY, CCM, PHI, RDY, TLK, ASLN, TIGR, WNS, DOYU, DUO, KRKR, CAN, CMCM, TOUR
  10:40 AM EDT, 05/21/2024 (MT Newswires) -- Asian equities traded in the US as American depositary receipts were trending lower Tuesday morning, declining 0.7% to 1,955.81 on the S&P Asia 50 ADR Index. From North Asia, the gainers were led by prope...

• Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia(R) & Xgeva(R) in the U.S., Europe and UK, from 10:05AM ET on Tuesday May 21, 2024 by Dow Jones

  10:05AM ET on Tuesday May 21, 2024 by Dow Jones
  Companies Mentioned: RDY, ALVO
  
  Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech's current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
  

• Alvotech and Dr. Reddy's Partner to Commercialize Biosimilar Candidate Denosumab, from 9:20AM ET on Tuesday May 21, 2024 by MT Newswires

  9:20AM ET on Tuesday May 21, 2024 by MT Newswires
  Companies Mentioned: RDY, ALVO
  09:20 AM EDT, 05/21/2024 (MT Newswires) -- Alvotech (ALVO) and Dr. Reddy's Laboratories (RDY) said Tuesday that they have partnered to commercialize AVT03, or denosumab, a biosimilar candidate to Prolia and Xgeva that addresses certain skeletal-rela...